Navigation Links
PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients
Date:2/1/2011

SOUTH PLAINFIELD, N.J. and HACKENSACK, N.J., Feb. 1, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) and Parent Project Muscular Dystrophy (PPMD) today announced an expansion of their collaboration to discover new treatments for patients with Duchenne/Becker muscular dystrophy (DBMD).  PPMD has awarded PTC a $250,000 grant, with the potential of additional funding, to advance drug discovery efforts in identifying a new treatment that improves heart function in patients with DBMD.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

PPMD's President Pat Furlong explained the decision for the grant, "The fight to end Duchenne and Becker muscular dystrophies must involve a comprehensive approach, considering all of the critical muscles that make up the human body.  The heart is a muscle too, and Parent Project Muscular Dystrophy has made cardiac health a top priority within our research investment for 2011.  PTC Therapeutics understood the importance of cardiac health from the moment we agreed to collaborate with them, now over ten years ago.  PTC continues to make our community's priorities their own and we are hopeful their approach to increase the level of SERCA2a protein will translate into healthier hearts for our sons."

Heart failure is a leading cause of death in patients with advanced DBMD.  Through the course of the disease, heart function is progressively compromised by calcium overload and inadequate transport, which leads to cell imbalance, dysfunction and death.  SERCA2a is a calcium ion pump found in heart tissue.  The goal of this research program is to identify new medicines that increase the amount of SERCA2a in the heart, resulting in improvements in calcium ion transport and heart function.  Using its proprietary drug discovery technology, PTC has identified early stage compounds that increase levels of SERCA2a protein.  The new PPMD grant will support medicinal chemistry efforts to improve the chemical, biological and pharmaceutical properties of these early molecules with the goal of identifying a development candidate for clinical studies.

"We are pleased to continue and expand our collaboration with PPMD in our ongoing effort to bring new treatments to Duchenne and Becker muscular dystrophy patients," stated Stuart W. Peltz, Ph.D., President & CEO of PTC Therapeutics.  "Our commitment to DBMD patients started more than a decade ago when we initiated our nonsense suppression program.  Those efforts led to ataluren, which has the potential to be the first therapy to treat the underlying cause of nonsense mutation DBMD.  Our experience developing ataluren will be beneficial to SERCA2a and our other neuromuscular programs as we move forward in development.  Our goal is to develop safe and effective treatments for all patients with DBMD."

About Parent Project Muscular Dystrophy

Parent Project Muscular Dystrophy (PPMD) is a national not-for-profit organization founded in 1994 by parents of children with Duchenne and Becker muscular dystrophy. The organization's mission is to improve the treatment, quality of life and long-term outlook for all individuals affected by Duchenne muscular dystrophy through research, advocacy, education and compassion. PPMD is headquartered in Middletown, Ohio with offices in Hackensack, New Jersey. For more information, visit www.parentprojectmd.org.

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and is the basis for collaborations with leading biopharmaceutical companies. For more information, visit the company's web site at www.ptcbio.com.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mederi Therapeutics Announces Receipt of FDA 510(k) Clearance for the MDRF1 Radiofrequency Generator
2. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
3. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
4. PTC Therapeutics President and CEO Elected AAAS Fellow
5. Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
6. ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
7. Echo Therapeutics to Present at the OneMedForum 2011 Conference
8. Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
9. Altheus Therapeutics Completes Phase I Clinical Study of Zoenasa™ in Ulcerative Colitis
10. Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million
11. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... LONDON , March 23, 2017 ... comprehensive research report created through extensive primary research ... research, the report aims to present the analysis ... basis of Procedure (Replacement and Repair); Replacement Procedure ... (TAVR)), Repair By Technique (Surgical Devices, Balloon Valvuloplasty, ...
(Date:3/23/2017)... 23, 2017  The U.S. Food and Drug Administration ... treatment of adults and pediatric patients 12 years and ... who have not received prior chemotherapy. This is the ... form of skin cancer. "While skin cancer ... a rare form called Merkel cell cancer have not ...
(Date:3/23/2017)... SAN DIEGO and VANCOUVER, British ... Inc. (NASDAQ: SPHS ) (the "Company" or ... for the treatment of urological diseases, today announced that ... which evaluated the drug as a focal treatment for ... on March 26, 2017 at the 32 nd ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its NAEMT Authorized ... providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned to ... developed in cooperation with the American College of Surgeons to promote critical thinking ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... world countries to hospitals in the United States, it’s a threat that is ... current obstacles facing infection prevention and offers strategies for the healthcare community to ...
(Date:3/24/2017)... Farifax, VA (PRWEB) , ... March 24, 2017 , ... ... its 2017 Quest Awards . The annual awards, now in their 12th year, ... marketing peers selects the winners. , In 2016, the awards were retooled to recognize ...
(Date:3/24/2017)... ... , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the ... clinic is the group’s 7th location in San Antonio and 23rd in Texas. ... care from the clinic, which opened March 22, 2017. , The team ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... related services to families and business owners across eastern Michigan, is connecting with ... families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ...
Breaking Medicine News(10 mins):